Article info

PDF

Concise report
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Authors

  1. Correspondence to Professor Stanley B Cohen, Metroplex Clinical Research Center, Dallas, TX 75231, USA; Scohen{at}arthdocs.com
View Full Text

Citation

Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Publication history

  • Received August 17, 2017
  • Revised January 31, 2018
  • Accepted February 7, 2018
  • First published March 7, 2018.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.